PharmStars graduates 10 digital health startups in spring 2026 cohort

By AI, Created 3:11 PM UTC, June 02, 2026, /AGP/ – PharmStars said 10 digital health startups completed its Spring 2026 PharmaU accelerator in Boston after a 10-week program focused on operations and outcomes. The cohort met with pharma members in more than 50 one-on-one sessions as the startup accelerator opened applications for its Fall 2026 immunology track.

Why it matters: - PharmStars aims to close the gap between digital health startups and pharma companies, where differences in speed, process and culture often slow partnerships. - The Spring 2026 graduates leave with direct access to pharma decision-makers, mentorship and industry feedback that can help turn pilot interest into commercial deals.

What happened: - PharmStars graduated 10 startups from its Spring 2026 cohort focused on “Digital Innovations in Operations & Outcomes.” - The cohort completed PharmaU, PharmStars’ 10-week educational and mentoring program. - PharmaU ended with a Startup Showcase in Boston for participating startups and PharmStars’ pharma members. - The Spring 2026 group marked PharmStars’ 10th accelerator cohort.

The details: - The 10 startups were selected through a competitive application process that drew applicants from 21 countries. - The cohort’s solutions span AI tools for lifecycle extension of compounds, patient data collection and modeling, clinical trials, patient and HCP engagement, quality and regulatory compliance, and HCP care coordination. - PharmaU pairs an industry-focused curriculum with mentorship from pharma experts. - The program is designed to help startups understand pharma structure, priorities and collaboration expectations. - Startups also get access to PharmStars’ pharma members as potential customers and sources of early feedback. - At the Startup Showcase, startups pitched their products to pharma members and then met privately with them. - Nearly 60 one-on-one meetings were set up between the startups and PharmStars’ pharma members. - Aditya Iyer, CEO of Allos AI, said the program helped the company sharpen how it communicates to pharma and that hands-on mentor engagement was especially valuable. - Nikolai Makaranka, founder and CEO of Daikon, said the one-on-one meetings were the most valuable part of PharmStars because such meetings are hard to secure independently.

Between the lines: - PharmStars is using the accelerator to make startup messaging, pharma relationships and early feedback less dependent on cold outreach. - The strong international application pool suggests digital health startups continue to see pharma partnerships as a meaningful route to scale. - The emphasis on operations and outcomes reflects pharma demand for tools that can improve efficiency and measurable performance, not just point solutions.

What’s next: - PharmStars is accepting applications for its Fall 2026 cohort focused on “Digital Innovations in Immunology.” - The accelerator is also taking a limited number of additional pharma and biotech members. - More information and applications are available at PharmStars’ website.

The bottom line: - PharmStars is turning its accelerator into a matchmaking channel for digital health startups and pharma partners, with the next cohort already open for applications.